IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma

Neuro-Oncology

Volumn 15, Issue 9, 2013, Pages 1114-1126

  Zhang, Chunzhi ^a,b   Moore, Lynette M ^a   Li, Xia ^a,c   Yung, W K Alfred ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TIANJIN HUANHU HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

2 HG; 2 hydroxyglutarate; glioma; IDH1 2 mutation; metabolism

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PROTEIN P53;

CANCER PROGNOSIS; CARCINOGENESIS; CELL METABOLISM; CHROMOSOME 19Q; CHROMOSOME 1P; DEMETHYLATION; DNA DAMAGE; DNA METHYLATION; GENE MUTATION; GLIOMA; HISTONE METHYLATION; HUMAN; LIPID PEROXIDATION; MISSENSE MUTATION; NONHUMAN; REVIEW; SOMATIC MUTATION;

2-HG; 2-HYDROXYGLUTARATE; GLIOMA; IDH1/2 MUTATION; METABOLISM;

BRAIN NEOPLASMS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 84883171570     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not087     Document Type: Review

References (102)

1. Hanahan D, Weinberg RA. Hallmarksofcancer: thenextgeneration. Cell. 2011;144:646-674.
2. Dang CV. Links between metabolism and cancer. Genes Dev. 2012; 26:877-890.
3. Prensner JR, Chinnaiyan AM. Metabolism unhinged: IDH mutations in cancer. Nat Med. 2011;17:291-293.
4. Israël M, Schwartz L. The metabolic advantage oftumor cells. Mol Cancer. 2011;10:70.
5. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744.
6. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033.
7. Frezza C, Zheng L, Folger O, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011;477: 225-228.
8. Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neopla-sia. Pathology. 2012;44:285-292.
9. Sjö blom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268-274. (Pubitemid 44571966)
10. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-1812.
11. Tang JY, Chang CC, Lin PC, Chang JG. Isocitratedehydrogenasemutation hot spots in acute lymphoblastic leukemia and oral cancer. Kaohsiung J Med Sci. 2012;28:138-144.
12. Ghiam AF, Cairns RA, Thoms J, et al. IDH mutation status in prostate cancer. Oncogene. 2012;31:3826.
13. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyp-ingofnon-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22:2616-2624.
14. Amary MF, Bacsi K, Maggiani F, et al. IDH1andIDH2mutationsare frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334-343.
15. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate de-hydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72-79.
16. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117:e198-e206.
17. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
18. Shen Y, Zhu YM, Fan X, et al. Genemutationpatterns andtheir prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118:5593-5603.
19. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114: 97-109. (Pubitemid 47103521)
20. Weller M, Cloughesy T, Perry JR, Wick W. Standardsofcare for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol. 2013; 15:4-27.
21. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29:4482-4490.
22. Xu X, Zhao J, Xu Z, et al. Structures ofhuman cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem. 2004;279:33946-33957. (Pubitemid 39063045)
23. Weller M, Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia. 2011;59:1200-1204.
24. Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glio-blastoma. PLoS One. 2011;6:e19868.
25. Leonardi R, Subramanian C, Jackowski S, Rock CO. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem. 2012;287:14615-14620.
26. Rokka A, Antonenkov VD, Soininen R, et al. Pxmp2 is a channel-forming proteininmammalianperoxisomal membrane.PLoSOne. 2009;4:e5090.
27. Lu Q, Minard KI, McAlister-Henn L.Dual compartmental localization and function of mammalian NADP+-specific isocitrate dehydrogenase in yeast. Arch Biochem Biophys. 2008;472:17-25.
28. Park SY, Lee SM, Shin SW, Park JW. Inactivation of mitochondrial NADP+-dependent isocitrate dehydrogenase by hypochlorous acid. Free Radic Res. 2008;42:467-473.
29. Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011; 481:385-388.
30. Koh HJ, Lee SM, Son BG, et al. CytosolicNADP+-dependentisocitratede- hydrogenase plays a key role in lipid metabolism. J Biol Chem. 2004; 279:39968-39974.
31. Ronnebaum SM, Ilkayeva O, Burgess SC, et al. A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J Biol Chem. 2006;281: 30593-30602. (Pubitemid 44582115)
32. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med. 2011;51:1289-1301.
33. Kim J, Kim KY, Jang HS, et al. Role of cytosolic NADP+-dependent isocitrate dehydrogenaseinischemia-reperfusion injury inmouse kidney.Am J Physiol Renal Physiol. 2009;296:F622-F633.
34. Shih AH, Levine RL. IDH1 mutations disrupt blood, brain, and barriers. Cancer Cell. 2012;22:285-287.
35. Ward PS, Lu C, Cross JR, et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem. 2013;288:3804-3815.
36. Hartmann C, Meyer J, Balss J, et al. Typeand frequencyofIDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol. 2009; 118:469-474.
37. Ward PS, Cross JR, Lu C, et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene. 2012;31:2491-2498.
38. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.
39. Narasimhaiah D, Miquel C, Verhamme E, Desclée P, Cosnard G, Godfraind C. IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology. 2012;32:30-37.
40. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glio-blastomas. Neuro Oncol. 2009;11:341-347.
41. Takano S, Tian W, Matsuda M, et al. DetectionofIDH1mutationinhuman gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011;28:115-123.
42. Horbinski C, Kofler J, Yeaney G, et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol. 2011;21:564-574.
43. Solis OE, Mehta RI, Lai A, et al. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. J Neurooncol. 2011;102:477-484.
44. Byeon SJ, Myung JK, Kim SH, Kim SK, Phi JH, Park SH. Distinct genetic alterations in pediatric glioblastomas. Childs Nerv Syst. 2012;28: 1025-1032.
45. Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomasWHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol. 2012;108:403-410.
46. Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012;18:2490-2501.
47. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226:7-16.
48. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutationsareearly eventsinthedevelopmentofastrocytomasandoligodendrogliomas.AmJ Pathol. 2009;174:1149-1153.
49. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3:709-722.
50. Lass U, Nü mann A, von Eckardstein K, et al. Clonal analysis inrecurrent as-trocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor-initiating event. PLoS One. 2012;7:e41298.
51. Figarella-Branger D, Bouvier C, de Paula AM, et al. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. J Neurooncol. 2012;110:205-213.
52. Badiali M, Gleize V, Paris S, et al. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol. 2012;22: 841-847.
53. Yan W, Zhang W, You G, et al. Correlation ofIDH1 mutation with clinico-pathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One. 2012;7:e30339.
54. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17:98-110.
55. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510-522.
56. SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012; 103:269-273.
57. Reitman ZJ, Jin G, Karoly ED, et al. Profiling the effects of isocitrate dehy-drogenase1 and 2mutationson the cellular metabolome.Proc Natl Acad Sci U S A. 2011;108:3270-3275.
58. Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339:1621-1625.
59. Steenweg ME, Jakobs C, Errami A, et al. An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. Hum Mutat. 2010;31:380-390.
60. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483:484-488.
61. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is acom-petitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17-30.
62. Pappalardi MB, McNulty DE, Martin JD, et al. Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites. Biochem J. 2011;436:363-369.
63. Jin G, Reitman ZJ, Spasojevic I, et al. 2-hydroxyglutarate production, but not dominantnegative function, is conferred byglioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One. 2011;6:e16812.
64. Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12:463-469.
65. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol. 2012;13:297-311.
66. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474-478.
67. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation issufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483:479-483.
68. Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One. 2012;7:e41036.
69. Sasaki M, Knobbe CB, Itsumi M, et al. D-2-hydroxyglutarate producedby mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 2012;26:2038-2049.
70. vanderZee JA, vanEijck CH, Hop WC, et al. Tumourbasementmembrane laminin expression predicts outcome following curative resection of pancreatic head cancer. Br J Cancer. 2012;107:1153-1158.
71. Hirashima K, Iyama KI, Baba Y, et al. Differential expression of basement membrane typeIVcollagen a2anda6 chainsasaprognosticfactorinpa-tients with extrahepatic bile duct carcinoma. J Surg Oncol. 2013;107:402-407.
72. Grassian AR, Lin F, Barrett R, et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/mir-200-dependent epithelial-mesenchymal (EMT) transition. J Biol Chem. 2012;287:42180-42194.
73. Benjamin DI, Cravatt BF, Nomura DK. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab. 2012;16:565-577.
74. Marin-Valencia I, Yang C, Mashimo T, et al. Analysisoftumor metabolism reveals mitochondrial glucose oxidationingenetically diverse human glio-blastomas in the mouse brain in vivo. Cell Metab. 2012;15:827-837.
75. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70:8981-8987.
76. Bralten LB, Kloosterhof NK, Balvers R, et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol. 2011;69: 455-463.
77. Bonner MY, Arbiser JL. Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Mol Life Sci. 2012;69:2435-2442.
78. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxida-tive damage to cells. Free Radic Biol Med. 2002;32:1185-1196. (Pubitemid 34603355)
79. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425-437.
80. Qi ST, Yu L, Lu YT, et al. IDH mutations occurfrequentlyinChinese glioma patients and predict longer survival but not response to concomitant che-moradiotherapy in anaplastic gliomas. Oncol Rep. 2011;26:1479-1485.
81. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun. 2009;390: 547-551.
82. Kaneko MK, Tian W, Takano S, et al. Establishment of anovel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun. 2011;406:608-613.
83. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol. 2009;68:1319-1325.
84. Kaneko MK, Morita S, Tsujimoto Y, et al. Establishmentofnovelmonoclo-nal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochem Biophys Res Commun. 2013;432:40-45.
85. Setty P, Hammes J, Rothämel T, et al. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn. 2010;12:750-756.
86. Sonoda Y, Kumabe T, Nakamura T, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009;100:1996-1998.
87. Hartmann C, Hentschel B, Tatagiba M, et al. Molecularmarkersinlow-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17:4588-4599.
88. Sahm F, Capper D, Pusch S, et al. Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatog-raphy/mass spectrometry. Brain Pathol. 2012;22:26-31.
89. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and2 mutations. JExp Med. 2010;207:339-344.
90. Capper D, Simon M, Langhans CD, et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer. 2012;131:766-768.
91. Boisselier B, Gállego Pérez-Larraya J, Rossetto M, et al. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology. 2012;79:1693-1698.
92. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-Hydroxyglutarate detection by magnetic resonance spectroscopy insubjects with IDH-mutated gliomas. Nat Med. 2012;18:624-629.
93. Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012;107:197-205.
94. Lazovic J, Soto H, Piccioni D, et al. Detection of 2-hydroxyglutaric acid in vivobyprotonmagneticresonancespectroscopyinU87 glioma cells over-expressing isocitrate dehydrogenase-1 mutation. Neuro Oncol. 2012;14: 1465-1472.
95. Jin G, Reitman ZJ, Duncan CG, et al. Disruption of wild type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res. 2013;73:496-501.
96. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340:626-630.
97. Wang F, Travins J, Delabarre B, et al. Targeted inhibitionof mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340:622-626.
98. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597-1604.
99. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261-265.
100. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4154.
101. Jha P, Suri V, Sharma V, et al. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol. 2011;91:385-393.
102. Mellai M, Piazzi A, Caldera V, et al. IDH1 and IDH2 mutations, immuno-histochemistry and associations in a series of brain tumors. J Neurooncol. 2011;105:345-357.